What Is the Prevalence of Retinitis Pigmentosa?

Retinitis pigmentosa affects roughly 1 in 3,750 to 1 in 4,000 people worldwide, making it the most common inherited retinal disease while still qualifying as a rare condition. That translates to more than 1.5 million people living with RP globally.¹ Those headline numbers, though, obscure wide variation depending on where someone lives, their ethnic background, and whether consanguinity is common in their community. The disease is also genetically complex enough that prevalence figures keep shifting as diagnostic tools improve.

How Prevalence Varies by Region and Population

The 1-in-4,000 figure is a widely cited global average, but local prevalence can be substantially higher or lower. A study in the Jerusalem region found RP prevalence among Arab Muslims was about 1 in 1,800, roughly double the global average, while prevalence among Jewish residents was about 1 in 2,230.² The main driver of that gap is consanguinity. When close relatives marry, the chance of a child inheriting two copies of the same recessive mutation climbs sharply. Populations with high rates of consanguineous marriage tend to show more autosomal recessive diseases in general, and RP is no exception.

In European countries, estimated diagnosed patient counts vary from roughly 24,000 in Germany to about 3,600 in Spain, though raw case counts also reflect population size and how actively countries screen for inherited eye diseases.¹ In a study of patients from understudied ethnic groups seen at Italian hospitals, RP was the most common inherited retinal disease overall, representing about 56% of cases. Among patients of African origin specifically, RP made up an even larger share, while cone dystrophy was more common in those from Eastern Europe.³ These patterns suggest that founder mutations, meaning rare variants that become common in an isolated or closely intermarried group, play a meaningful role in shaping where RP clusters geographically.

Inheritance Patterns and Their Effect on Prevalence

RP is not one disease with one genetic cause. Over 80 genes can produce the condition, and they follow different inheritance patterns. A large U.S. study estimated that about 84% of RP cases are autosomal recessive, roughly 10% are autosomal dominant, and about 6% are X-linked recessive.⁴ The recessive form dominates because a person needs two faulty copies of the same gene to develop the disease, and many people carry one copy without ever knowing it. The dominant form requires only one copy, so it tends to run visibly through families. X-linked cases predominantly affect males and tend to cause the most severe vision loss.

This genetic diversity matters for prevalence estimates because different populations carry different founder mutations at different rates. In Spain, for instance, among families with autosomal dominant RP, the RHO gene was the most commonly mutated, accounting for about 31% of characterized families. Among autosomal recessive families, USH2A was the leading gene at about 19%, but over 70 different disease genes were identified across those families.⁵ That level of genetic fragmentation means that even in a single country, RP is really dozens of genetically distinct conditions that converge on the same clinical picture of progressive vision loss.

How Many People Carry RP Mutations Without Knowing

One of the more striking findings in recent genetics research is just how many unaffected people carry a recessive mutation that could cause an inherited retinal disease. An analysis of global carrier frequencies estimated that about 2.7 billion people, roughly 36% of the world’s population, carry at least one mutation capable of causing autosomal recessive inherited retinal disease. Among Europeans, the carrier rate was about 1 in 2.26 individuals; among Finnish populations it was lower, about 1 in 3.50.⁶ That makes this group of conditions among the most commonly carried recessive disorders in the human genome.

Most carriers never develop any symptoms, because they have one working copy of the gene doing its job. The risk emerges when two carriers of the same gene happen to have children together. Carrier frequency data like this helps explain why RP continues to appear in families with no history of eye disease: the recessive mutations circulate silently through the population until two converge in one child. For specific subtypes the carrier numbers are much smaller. In East Asian populations, carrier frequency for RPE65-related disease, one of the few forms treatable with gene therapy, was estimated at only about 0.1%.⁷

Syndromic Versus Non-Syndromic Forms

When people think of RP, they usually picture isolated vision loss. That describes the majority of cases: about 70 to 80% of RP is non-syndromic, meaning the retina is the only organ affected.¹ But the remaining 20 to 30% of cases come bundled with other medical problems, and knowing this matters for both patients and doctors trying to understand prevalence data.

A Danish epidemiological study broke down the syndromic cases: Usher syndrome, which combines RP with hearing loss, accounted for about 12% of all RP cases. Bardet-Biedl syndrome, which adds obesity, kidney problems, and other features to the retinal degeneration, made up about 5%. Rarer syndromes accounted for the remaining small percentages.⁸ These syndromic forms sometimes get counted separately in disease registries, which can make RP prevalence look artificially low if only the non-syndromic category is reported. A patient with Usher syndrome has RP, but their case may appear in audiology records rather than ophthalmology databases.

There are also unusual phenotypic variants. Retinitis punctata albescens, for example, is an autosomal recessive form characterized by distinctive white dot-like deposits in the fundus, most often caused by mutations in the RLBP1 gene.⁹ Variants like these are rare enough that they barely register in prevalence figures individually, but collectively they add texture to the overall RP landscape.

When Symptoms Appear and How Fast Vision Declines

RP is a disease that usually announces itself in adolescence or young adulthood but takes decades to reach its worst stages. Over three-quarters of patients develop their first symptoms by age 30, typically night blindness or difficulty adjusting between light and dark environments. Despite early symptoms, the average age of formal diagnosis is about 35 years, reflecting a real gap between when patients notice something is wrong and when clinicians confirm the cause.¹⁰ In Korea, a nationwide population study found the average age at diagnosis was even later, around 45 years, potentially reflecting different referral patterns or clinical thresholds for diagnosis.¹¹

The speed of decline depends heavily on the genetic subtype. People with autosomal recessive forms tend to become symptomatic in their early teens, while those with dominant forms may not notice problems until their twenties or thirties, and in some cases not until after 50. X-linked RP is the most aggressive: patients with this form are about four times more likely to be legally blind compared to those with dominant RP, and they reach that threshold by an average age of 45.¹⁰ Most patients across all subtypes are classified as legally blind by around age 40, though complete blindness is relatively uncommon. Central vision often persists for years after the peripheral field has collapsed to tunnel vision.

Complications That Accelerate Vision Loss

RP does not degrade the retina in isolation. It frequently triggers secondary eye problems that pile on additional vision loss, and these complications are more common than many patients expect. In a study of 169 RP patients, cystoid macular edema (fluid-filled cysts in the central retina) was present in nearly 59% of patients, and it was bilateral in about three-quarters of those affected. Epiretinal membranes were found in about 23% of eyes, and cataracts in a similar proportion.¹²

The cataract issue deserves special attention. While cataracts are common in older adults generally, RP patients tend to develop a specific type, posterior subcapsular cataracts, at younger ages than the general population.¹³ This means a 30-year-old RP patient may have cataract-related glare and haze layered on top of the retinal degeneration already narrowing their visual field. Cataract surgery can help restore clarity in the remaining visual field, but the overall prognosis for the retina itself does not change.

RP as a Cause of Legal Blindness

Despite being classified as rare, RP punches above its weight as a cause of blindness because it strikes young and progresses over an entire adult lifetime. In the Oregon Commission for the Blind registry, RP accounted for about 6% of all registered blind individuals, placing it alongside glaucoma in frequency. Critically, the mean age at onset of blindness for RP was just 27 years, far younger than the averages for glaucoma (48), diabetic retinopathy (42), or age-related macular degeneration (68). Among registrants under 40, RP was one of the leading causes of vision loss.¹⁴

That early onset means decades of lost productivity, career limitations, and escalating care needs. The economic burden of RP includes greater healthcare spending, reduced earning capacity, and a growing dependence on both formal and informal caregiving as vision declines through middle age.¹⁵ In countries that track childhood blindness separately, there is some encouraging news: in Israel, a decline in severe visual impairment among children was partly attributable to decreased blindness from RP.¹⁶ Whether that reflects better genetic counseling, reduced consanguinity in some communities, or other factors is still being studied.

Diagnostic Challenges and the Role of Genetic Testing

Getting accurate prevalence data for RP is harder than it might seem. The disease presents in many different ways, progresses at different rates depending on the genetic subtype, and overlaps clinically with other retinal conditions. A lack of community awareness about early signs of RP, combined with varied clinical presentations, creates barriers to timely diagnosis.¹⁷ Someone with mild night blindness in their teens may not see an ophthalmologist for years, and the initial clinical exam may not immediately distinguish RP from other causes.

Genetic testing has reshaped how RP is diagnosed and, indirectly, how prevalence is measured. Broad sequencing panels now test for mutations across dozens or even all known retinal dystrophy genes simultaneously. In one study, next-generation sequencing identified disease-causing mutations in about 70% of analyzed RP patients, a rate the authors considered high compared to earlier approaches.¹⁸ When patients who had previously gone undiagnosed were re-tested using whole-exome sequencing, the diagnostic yield climbed to about 89%, substantially better than the 50 to 70% range seen in earlier targeted panels.¹⁹

As testing becomes cheaper and more widely available, more patients who were previously labeled with “retinal dystrophy, cause unknown” are getting specific genetic diagnoses. That shifts the apparent prevalence of known RP subtypes upward, even though the actual number of affected people has not changed. It also means prevalence estimates from the 1990s and earlier likely undercount RP, particularly in regions where genetic testing was unavailable or limited to a few research centers.

Why Gene Therapy Eligibility Is So Narrow

The approval of voretigene neparvovec (sold as Luxturna) in 2017 was a milestone for RP patients, but the treatment applies only to the small fraction of cases caused by biallelic mutations in the RPE65 gene. In a Turkish screening study of 460 patients with inherited retinal dystrophies, only about 2.4% had the right RPE65 mutations. Even among those 11 patients, not all were eligible for treatment: some had visual acuity too poor to perform the required mobility tests, and others had macular thickness below the 100 micrometer threshold needed for the therapy to work, because the retinal cells it targets had already degenerated.²⁰ In that study, fewer than half of the RPE65-positive patients met all the criteria.

This illustrates a broader frustration in the RP treatment landscape. The genetic fragmentation that makes RP so varied also makes it extraordinarily difficult to treat at scale. A gene therapy that fixes one gene helps only the patients with mutations in that specific gene, and for most of the 80-plus genes involved, no targeted therapy exists yet. Clinical trials for additional gene targets, as well as gene-agnostic approaches like optogenetics and retinal prosthetics, are underway, but they remain years from widespread availability. For the moment, the vast majority of the 1.5 million people with RP worldwide have no treatment that can halt or reverse their vision loss.

What Dog Breeds Reveal About RP Genetics

RP research has an unexpected ally in veterinary medicine. Dogs develop a naturally occurring condition called progressive retinal atrophy (PRA) that closely mirrors human RP: rod photoreceptors die first, followed by cones, leading to night blindness and eventually total vision loss. Out of roughly 400 recognized breeds, nearly 100 have an inherited form of PRA, each caused by mutations in specific genes that often have direct human counterparts.²¹ The Briard, a French herding breed, was the model organism for developing the RPE65 gene therapy that eventually became Luxturna. The breed-specific nature of PRA means that individual dog breeds effectively isolate single genetic mutations in large, naturally occurring populations, something almost impossible to find in humans outside of highly consanguineous communities. This has made certain breeds invaluable for understanding how specific mutations cause photoreceptor death and for testing whether a therapy works before moving to human trials.